[go: up one dir, main page]

CR10654A - Agentes que comprenden compuestos marcados con 18f y metodos relacionados - Google Patents

Agentes que comprenden compuestos marcados con 18f y metodos relacionados

Info

Publication number
CR10654A
CR10654A CR10654A CR10654A CR10654A CR 10654 A CR10654 A CR 10654A CR 10654 A CR10654 A CR 10654A CR 10654 A CR10654 A CR 10654A CR 10654 A CR10654 A CR 10654A
Authority
CR
Costa Rica
Prior art keywords
agents
related methods
compounds
compounds marked
understanding
Prior art date
Application number
CR10654A
Other languages
English (en)
Inventor
Lutz Lehamann
Ananth Srinivasan
Thomas Brumby
Detlev Sulzle
Timo Stellfeld
Keith Graham
Mylene Karramkam
Simon Ametamey
Original Assignee
Bayer Schering Pharma Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP06090166A external-priority patent/EP1897885A1/en
Priority claimed from EP07090079A external-priority patent/EP1985624A3/en
Application filed by Bayer Schering Pharma Ag filed Critical Bayer Schering Pharma Ag
Publication of CR10654A publication Critical patent/CR10654A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/655—Somatostatins
    • C07K14/6555—Somatostatins at least 1 amino acid in D-form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/088—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins conjugates with carriers being peptides, polyamino acids or proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C255/00—Carboxylic acid nitriles
    • C07C255/49—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C07C255/58—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton containing cyano groups and singly-bound nitrogen atoms, not being further bound to other hetero atoms, bound to the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/57545—Neuropeptide Y

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Genetics & Genomics (AREA)
  • Endocrinology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pyridine Compounds (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Hydrogenated Pyridines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

La presente invencion se relaciona con compuestos novedosos adecuados para ser marcadso o ya marcados radioactivamente con 18F, metodos para obtener dichos compuestos y uso de tales compuestos como agentes de diagnostico por imagenes. Dichos compuestos marcadas se caracterizan por presentar la Formula II, en donde los sustituyentes G, Q, L, Y y U tienen el significado defindo en la memoria descriptiva y en las reivindicaciones.
CR10654A 2006-09-08 2009-03-05 Agentes que comprenden compuestos marcados con 18f y metodos relacionados CR10654A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP06090166A EP1897885A1 (en) 2006-09-08 2006-09-08 Compounds and methods for F labelled agents
EP07090079A EP1985624A3 (en) 2007-04-23 2007-04-23 Single step method of radiofluorination of biologically active compounds or biomolecules

Publications (1)

Publication Number Publication Date
CR10654A true CR10654A (es) 2009-04-14

Family

ID=39031005

Family Applications (1)

Application Number Title Priority Date Filing Date
CR10654A CR10654A (es) 2006-09-08 2009-03-05 Agentes que comprenden compuestos marcados con 18f y metodos relacionados

Country Status (20)

Country Link
US (1) US8557776B2 (es)
EP (5) EP3056509A1 (es)
JP (2) JP5603074B2 (es)
KR (1) KR20090058553A (es)
AR (1) AR062726A1 (es)
AU (1) AU2007294124A1 (es)
BR (1) BRPI0716554A2 (es)
CA (2) CA2858907A1 (es)
CL (1) CL2007002620A1 (es)
CO (1) CO6150196A2 (es)
CR (1) CR10654A (es)
IL (4) IL197363A0 (es)
MA (1) MA30780B1 (es)
MX (1) MX2009002492A (es)
NO (1) NO20091428L (es)
PE (1) PE20080850A1 (es)
RU (1) RU2009112716A (es)
TN (1) TN2009000063A1 (es)
TW (1) TW200829277A (es)
WO (1) WO2008028688A2 (es)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8557776B2 (en) 2006-09-08 2013-10-15 Bayer Pharma AG Compounds and methods for 18F labeled agents
US20090317326A1 (en) * 2007-03-01 2009-12-24 Ananth Srinivasan Radiofluorination methods
GB201013808D0 (en) 2010-08-18 2010-09-29 Ge Healthcare Ltd Peptide radiotracer compositions
WO2012094334A1 (en) * 2011-01-04 2012-07-12 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services One-step 18f labeling of biological substrates and uses of 18f labeled biological substrates
JP2014526952A (ja) * 2011-06-09 2014-10-09 ジーイー・ヘルスケア・リミテッド 蒸留装置及び方法
ES2743433T3 (es) * 2013-03-15 2020-02-19 Cancer Targeted Tech Llc Agentes para imágenes de pet dirigidos a psma marcados con 18F
GB201314936D0 (en) 2013-08-21 2013-10-02 Ge Healthcare Ltd Radiolabelling method
GB201322456D0 (en) 2013-12-18 2014-02-05 Ge Healthcare Ltd Radiotracer compositions and methods
US11518754B2 (en) 2017-02-17 2022-12-06 Yale University Radiolabeled pharmaceuticals and methods of making and using same
IL271903B2 (en) 2017-07-11 2025-04-01 Synthorx Inc Combination of unnatural nucleotides and methods therefor
SG11202000939PA (en) 2017-08-03 2020-02-27 Synthorx Inc Cytokine conjugates for the treatment of proliferative and infectious diseases
US20210238124A1 (en) * 2018-04-20 2021-08-05 The General Hospital Corporation Acetylated prodrugs for delivery across the blood-brain barrier
EP3923974A4 (en) 2019-02-06 2023-02-08 Synthorx, Inc. IL-2 CONJUGATES AND METHODS OF USE THEREOF
CN113150065B (zh) * 2021-03-11 2022-07-08 武汉英纳氏药业有限公司 一种合成肽及其应用
WO2022246118A2 (en) * 2021-05-20 2022-11-24 The Regents Of The University Of California Pet imaging tracers
KR20250164815A (ko) 2023-03-31 2025-11-25 닛산 가가쿠 가부시키가이샤 피라졸 화합물 및 유해 생물 방제제

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5084555A (en) 1989-08-21 1992-01-28 The Administrators Of The Tulane Educational Fund An octapeptide bombesin analog
JP2795449B2 (ja) * 1987-09-24 1998-09-10 ジ・アドミニストレーターズ・オブ・ザ・ツーレイン・エデュケイショナル・ファンド 治療用ペプチド
US5723578A (en) * 1987-09-24 1998-03-03 The Administrators Of Tulane Educational Fund Peptide analogs of bombesin
DE68928667T2 (de) * 1988-10-14 1998-10-01 Univ Tulane Peptide als arzneimittel
JP2846463B2 (ja) * 1989-06-02 1999-01-13 ジョージタウン・ユニバーシティー 抗ストレプトキナーゼ抗体の検出方法
US6232071B1 (en) 1990-06-11 2001-05-15 Gilead Sciences, Inc. Tenascin-C nucleic acid ligands
US5244883A (en) * 1990-11-29 1993-09-14 The Administrators Of The Tulane Educational Fund Nonapeptide bombesin antagonists
TW432073B (en) * 1995-12-28 2001-05-01 Pfizer Pyrazolopyridine compounds
AU2010299A (en) 1997-12-24 1999-07-19 Vertex Pharmaceuticals Incorporated Prodrugs os aspartyl protease inhibitors
WO1999033795A1 (en) 1997-12-24 1999-07-08 Vertex Pharmaceuticals Incorporated Prodrugs of aspartyl protease inhibitors
ID25551A (id) 1997-12-24 2000-10-12 Vertex Pharma Bahan baku obat penghambat protease aspartil
US6436989B1 (en) 1997-12-24 2002-08-20 Vertex Pharmaceuticals, Incorporated Prodrugs of aspartyl protease inhibitors
US6639076B1 (en) 1998-08-18 2003-10-28 Eli Lilly And Company Growth hormone secretagogues
JP2003502314A (ja) 1999-06-14 2003-01-21 イーライ・リリー・アンド・カンパニー 化合物
WO2002044144A2 (en) * 2000-11-30 2002-06-06 Advanced Research And Technology Institute, Inc. Nucleophilic approach for preparing radiolabeled imaging agents and associated compounds
GB0115927D0 (en) 2001-06-29 2001-08-22 Nycomed Amersham Plc Solid-phase nucleophilic fluorination
GB0206750D0 (en) 2002-03-22 2002-05-01 Amersham Plc Radiofluorination methods
ATE332307T1 (de) 2002-04-09 2006-07-15 Lilly Co Eli Wachstumhormonsekretionsförderer
AU2003250899A1 (en) * 2002-08-09 2004-03-11 Astellas Pharma Europe B.V. Compounds binding to p-selectin
US20080063599A1 (en) 2002-11-18 2008-03-13 Jorge Setoain Quinquer Compounds Which Can Be Used To Diagnose And Monitor Diseases Associated With The Formation Of Amyloid Protein Fibrils
EP1597270A2 (en) 2003-02-20 2005-11-23 University of South Florida Peptidomimetic inhibitors of stat3 activity and their medical uses
GB0305704D0 (en) 2003-03-13 2003-04-16 Amersham Plc Radiofluorination methods
WO2006083424A2 (en) 2004-12-28 2006-08-10 The Trustees Of Columbia University In The City Of New York Radiolabeled compounds and uses thereof
CN101583352A (zh) 2005-07-29 2009-11-18 拜尔健康护理有限责任公司 治疗肥胖症的联苯氨基酸衍生物的制备和用途
US20080029548A1 (en) 2006-05-05 2008-02-07 Ann De Wree Fabric treatment dispensing package
US8557776B2 (en) 2006-09-08 2013-10-15 Bayer Pharma AG Compounds and methods for 18F labeled agents

Also Published As

Publication number Publication date
EP2063918B1 (en) 2014-02-26
JP2010503618A (ja) 2010-02-04
WO2008028688A3 (en) 2008-11-13
EP2279759A3 (en) 2013-04-17
WO2008028688A2 (en) 2008-03-13
EP3056509A1 (en) 2016-08-17
CA2662449A1 (en) 2008-03-13
RU2009112716A (ru) 2010-10-20
NO20091428L (no) 2009-06-03
IL211527A0 (en) 2011-05-31
IL211526A0 (en) 2011-05-31
BRPI0716554A2 (pt) 2013-09-24
PE20080850A1 (es) 2008-09-02
EP2289564A3 (en) 2012-11-14
EP2289564A2 (en) 2011-03-02
IL211033A0 (en) 2011-04-28
JP5603074B2 (ja) 2014-10-08
KR20090058553A (ko) 2009-06-09
TN2009000063A1 (en) 2010-08-19
TW200829277A (en) 2008-07-16
JP5722966B2 (ja) 2015-05-27
MX2009002492A (es) 2009-08-28
AR062726A1 (es) 2008-11-26
CL2007002620A1 (es) 2008-05-30
IL197363A0 (en) 2011-08-01
AU2007294124A1 (en) 2008-03-13
CA2858907A1 (en) 2008-03-13
CO6150196A2 (es) 2010-04-20
EP2063918A2 (en) 2009-06-03
MA30780B1 (fr) 2009-10-01
US20080292548A1 (en) 2008-11-27
EP2455105B1 (en) 2016-02-17
EP2279759A2 (en) 2011-02-02
EP2455105A3 (en) 2012-09-05
US8557776B2 (en) 2013-10-15
JP2014028813A (ja) 2014-02-13
EP2455105A2 (en) 2012-05-23

Similar Documents

Publication Publication Date Title
CR10654A (es) Agentes que comprenden compuestos marcados con 18f y metodos relacionados
CR11861A (es) Compuestos organicos
UY32611A (es) Compuestos de 1-cianoetilheterociclilcarboxamida sustituidos 750
CR20120264A (es) Compuestos
CO6321189A2 (es) Compuestos de tiazol y oxazol de bencen-sulfonamida
CO6620055A2 (es) Ciertas amino-pirimidinas, composiciones de las mismas y métodos para el uso de los mismos
ECSP14013245A (es) Nuevos derivados dihidroquinolina-2-ona
ECSP10010129A (es) Inhibidores de quinasas símil polo
CR20140275A (es) Triazolopiridinas sustituidas
CR20110135A (es) INHIBIDORES DE cMET
UY31524A1 (es) Nuevos compuestos 010
CU20120084A7 (es) Compuestos derivados de triazolopiridina sustituidos como inhibidores de la quinasa mps-1 y compuestos intermediarios para su preparación
UY32918A (es) Nuevos compuestos de 2-piridona
CR11427A (es) 2-fluoro-2 - desoxitetrahidrouridinas como inhibidores de citidina desaminasa
CR20110558A (es) ANTICUERPOS ANTI-FcRH5 E INMUNOCONJUGADOS Y MÉTODOS DE USO
UY32863A (es) COMPUESTOS DE HEXAHIDROOXAZINOPTERINA PARA USO COMO INHIBIDORES DE mTOR
UY32077A (es) Inhibidores de quinasa tipo polo
CR9786A (es) Compuestos de bencimidazol-tiofeno
ECSP11011344A (es) Nuevos anticuerpos anti-?5?1 y sus usos
GT201300254A (es) Triazolopiridinas
ECSP12012338A (es) Triazolopiridinas sustituidas
PA8855001A1 (es) Monocarbamas
CR20140135A (es) Nuevos derivados de aril-quinolina
UY29469A1 (es) Compuestos sulfoximino-macrocíclicos y sus sales, composiciones farmacéuticas que comprenden dichos compuestos, métodos de preparación y usos de los mismos.
UY31905A (es) Derivados de benzoxazinona, procesos de preparación, composiciones farmacéuticas conteniéndolos y aplicaciones.

Legal Events

Date Code Title Description
FA Abandonment or withdrawal (granting procedure)